Last edition
News about "Addex Therapeutics"
Neurosterix Completes Phase 1 Studies of NTX-253 for Schizophrenia
Neurosterix has completed Phase 1 studies of NTX-253 and plans to begin Phase 2 development; Addex retains a 20 percent equity interest in the company.
Addex Therapeutics | 09/10/2026 | By News Bureau
Addex Therapeutics Reports Promising Preclinical Results for Novel Chronic Cough Therapy
Addex Therapeutics’ experimental GABAB modulator shows potential as a well-tolerated, long-term treatment option for chronic cough, addressing a significant unmet need in idiopathic pulmonary fibrosis patients.
Addex Therapeutics | 04/05/2026 | By News Bureau | 135
Addex Therapeutics Reports Promising Preclinical Results for Novel Chronic Cough Therapy
Addex Therapeutics’ experimental GABAB modulator shows potential as a well-tolerated, long-term treatment option for chronic cough, addressing a significant unmet need in idiopathic pulmonary fibrosis patients.
Addex Therapeutics | 04/05/2026 | By News Bureau | 135
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy